Strong emerging rationale for combining oncogene-targeted agents with immunotherapy

In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yan, Lizée, Gregory, Hwu, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601155/
https://www.ncbi.nlm.nih.gov/pubmed/23524978
http://dx.doi.org/10.4161/onci.22730
_version_ 1782475726111375360
author Yang, Yan
Lizée, Gregory
Hwu, Patrick
author_facet Yang, Yan
Lizée, Gregory
Hwu, Patrick
author_sort Yang, Yan
collection PubMed
description In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data support the notion that combining targeted agents with immunotherapy may constitute a promising approach for cancer therapy.
format Online
Article
Text
id pubmed-3601155
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36011552013-03-22 Strong emerging rationale for combining oncogene-targeted agents with immunotherapy Yang, Yan Lizée, Gregory Hwu, Patrick Oncoimmunology Author's View In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data support the notion that combining targeted agents with immunotherapy may constitute a promising approach for cancer therapy. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601155/ /pubmed/23524978 http://dx.doi.org/10.4161/onci.22730 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Yang, Yan
Lizée, Gregory
Hwu, Patrick
Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
title Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
title_full Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
title_fullStr Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
title_full_unstemmed Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
title_short Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
title_sort strong emerging rationale for combining oncogene-targeted agents with immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601155/
https://www.ncbi.nlm.nih.gov/pubmed/23524978
http://dx.doi.org/10.4161/onci.22730
work_keys_str_mv AT yangyan strongemergingrationaleforcombiningoncogenetargetedagentswithimmunotherapy
AT lizeegregory strongemergingrationaleforcombiningoncogenetargetedagentswithimmunotherapy
AT hwupatrick strongemergingrationaleforcombiningoncogenetargetedagentswithimmunotherapy

Ejemplares similares